AU622404B2 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
AU622404B2
AU622404B2 AU17681/88A AU1768188A AU622404B2 AU 622404 B2 AU622404 B2 AU 622404B2 AU 17681/88 A AU17681/88 A AU 17681/88A AU 1768188 A AU1768188 A AU 1768188A AU 622404 B2 AU622404 B2 AU 622404B2
Authority
AU
Australia
Prior art keywords
dipyridamole
interferon
tumor
huifn
patient suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU17681/88A
Other languages
English (en)
Other versions
AU1768188A (en
Inventor
Nobuo Suzuki
Takakubo Yoshiaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU1768188A publication Critical patent/AU1768188A/en
Application granted granted Critical
Publication of AU622404B2 publication Critical patent/AU622404B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU17681/88A 1987-06-16 1988-06-15 Pharmaceutical compositions Ceased AU622404B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE87108708 1987-06-16
EP87108708A EP0295317A1 (en) 1987-06-16 1987-06-16 Pharmaceutical composition for the treatment of tumors

Publications (2)

Publication Number Publication Date
AU1768188A AU1768188A (en) 1988-12-22
AU622404B2 true AU622404B2 (en) 1992-04-09

Family

ID=8197069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17681/88A Ceased AU622404B2 (en) 1987-06-16 1988-06-15 Pharmaceutical compositions

Country Status (11)

Country Link
US (1) US4997645A (enExample)
EP (2) EP0295317A1 (enExample)
JP (1) JPS63316722A (enExample)
KR (1) KR890000108A (enExample)
AT (1) ATE59780T1 (enExample)
AU (1) AU622404B2 (enExample)
DE (1) DE3861494D1 (enExample)
DK (1) DK328088A (enExample)
HU (1) HU200942B (enExample)
PH (1) PH27069A (enExample)
ZA (1) ZA884262B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US6003516A (en) * 1992-06-03 1999-12-21 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
SE513429C2 (sv) * 1992-06-03 2000-09-11 Syntello Inc Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
US5480640A (en) * 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US6155266A (en) * 1995-05-08 2000-12-05 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
JP7641894B2 (ja) * 2018-09-27 2025-03-07 アイテオ ベルギウム エスエー がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499093A (en) * 1982-01-19 1985-02-12 Dso "Pharmachim" Interferon induction method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499093A (en) * 1982-01-19 1985-02-12 Dso "Pharmachim" Interferon induction method

Also Published As

Publication number Publication date
HUT47033A (en) 1989-01-30
ATE59780T1 (de) 1991-01-15
EP0295559A2 (en) 1988-12-21
EP0295559A3 (en) 1989-03-08
JPH0529365B2 (enExample) 1993-04-30
EP0295317A1 (en) 1988-12-21
DK328088D0 (da) 1988-06-15
PH27069A (en) 1993-02-01
EP0295559B1 (en) 1991-01-09
US4997645A (en) 1991-03-05
KR890000108A (ko) 1989-03-11
DK328088A (da) 1988-12-17
ZA884262B (en) 1990-02-28
JPS63316722A (ja) 1988-12-26
HU200942B (en) 1990-09-28
AU1768188A (en) 1988-12-22
DE3861494D1 (de) 1991-02-14

Similar Documents

Publication Publication Date Title
EP0493468B1 (en) Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists
CA2136952C (en) Preparation for activation of natural killer cells (nk-cells), said preparation containing interferon-– and histamine, serotonin, amines or substances with corresponding receptor activity
Willemse et al. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer
CA2014130A1 (en) Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions
AU622404B2 (en) Pharmaceutical compositions
EP0831877B1 (en) Metabolic effects of certain glutathione analogs
US5215744A (en) Methods for the treatment of tumors
PT99265B (pt) Processo para a preparacao de composicoes farmaceuticas contendo interferon humano e metodo de tratamento de doencas proliferativas celulares
DK162923B (da) Farmaceutisk praeparat til inhibering af tumorcellevaekst og fremgangsmaade til fremstilling deraf
US6305380B1 (en) Method for treatment of cancer and infectious disease
EP0344643B1 (en) Antiviral pharmaceutical composition
Rizzo et al. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma
US5849282A (en) Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
US20190374611A1 (en) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
Zucali et al. Hematopoietic effects of interleukin-1
CA3106783A1 (en) Combination therapy for treating cancer
Zaniboni et al. 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study
AU672610C (en) Preparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin or substances with corresponding receptor activity
JP4684513B2 (ja) Ｇｖｈｄ抑制用医薬組成物
JPS623814B2 (enExample)
HK1128234B (en) Combination comprising combretastatin and anticancer agents
HK1128234A1 (en) Combination comprising combretastatin and anticancer agents